Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma
Table 1
Baseline characteristics for all patients.
Variables
TACE-RFA (n = 209)
TACE (n = 195)
value
Gender (male/female)
184/25
165/30
0.384
Age (years)#
59.2 ± 4.0 (18–75)
58.7 ± 4.0 (20–75)
0.872
HBsAg (+/−)
180/29
176/19
0.221
HCV (+/−)
10/199
7/188
0.625
ALT (U/L)#
27.2 ± 12.0 (16.5–78.2)
29.0 ± 11.9 (15.9–77.0)
0.789
ALB (g/L)#
35.7 ± 3.0 (33.0–49.0)
35.9 ± 3.4 (32.4–47.0)
0.876
Total bilirubin (μmol/L)#
12.8 ± 4.2 (7.0–22.0)
12.3 ± 4.5 (6.3–22.0)
0.902
GGT (U/L)#
106.0 ± 51.0 (49.0–422.0)
103.5 ± 61.0 (52.5–434.3)
0.675
Platelet count (×109/L)#
125.2 ± 25.9 (75–401)
130.2 ± 28.2 (80–403)
0.710
Prothrombin activity (%)#
98.0 ± 19.0 (78–120)
98.0 ± 18.4 (77–119)
0.735
AFP (ng/ml)
0.762
≤400
123
111
>400
86
84
Tumor size (cm)
0.840
≤3
125
114
>3
84
81
Tumor number
0.447
1
58
61
>1
151
134
Child–Pugh class (A/B)
189/20
180/15
0.596
Antiviral treatment for hepatitis B (yes/no)
108/101
99/96
0.921
#Data are represented in mean ± standard deviation. Data in parentheses are ranges. Except where indicated, data values represent the number of patients. TACE: transarterial chemoembolization; RFA: radiofrequency ablation; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; ALT: alanine aminotransferase; ALB: albumin; GGT: γ-glutamyl transpeptidase; AFP: alpha fetoprotein.
